Etiology of the anemia/underlying disease

N

F/M

Median age

Age range

Normal non-diabetic subjects

36

19/17

54

31 - 73

Non-anemic diabetic patients

18

9/9

59

43 - 74

Non-anemic control subjects in total

54

28/26

57

31 - 74

Iron-deficiency anemia

48

35/13

39

20 - 72

Megaloblastic anemia

56

37/19

72

31 - 88

Anemia of chronic disease

38

13/25

60

34 - 75

Hemolytic anemia

24

10/14

55

25 - 78

β-thalassemic trait

41

20/21

49

36 - 69

β-thalassemia major

92

42/50

31

16 - 71

Sickle-cell/β-thalassemic trait

23

10/13

33

18 - 56

Aplastic anemia

20

9/ 11

42

23 - 74

Other anemias

6

4/2

47

27 - 61

Non-MDS anemias in total

348

180/168

48

16 - 88

MDS-refractory anemia

102

33/69

71

41 - 87

MDS-RA with ringed side roblasts

46

14/32

73

37 - 88

MDS-RA with excess of blasts

92

19/73

68

45 - 87

MDS-RAEB in transformation

13

5 / 8

70

58 - 87

MDS-CMML

59

12/47

74

36 - 85

MDS-unclassified & hybrid MDS/MPN

14

1 /13

75

64 - 83

MDS in total

326

84/242

73

37 - 88

Polycythemia vera

38

14/24

58

45 - 80

Essential thrombocythemia

62

33/29

49

17 - 82

Myelofibrosis

32

7/25

65

38 - 87

Ph+ chronic myelogenous leukemia

18

3/15

47

29 - 78

Acute myelogenous leukemia

23

6/17

64

31 - 81

Myeloproliferative syndromes in total

173

63/110

56

17 - 87

Acute lymphoblastic leukemia

2

1/1

42

18 - 67

Non Hodgkin’s lymphoma

34

11/23

63

31 - 83

Hodgkin’s lymphoma

8

2/6

36

29 - 72

Chronic lymphocytic leukemia

30

15/15

68

40 - 79

Hairy-cell leukemia

8

2/6

62

49 - 75

Plasma-cell dyscrasias

78

39/39

66

38 - 84

Lymphoproliferative disorders in total

161

70/91

65

18 - 84

Secondary erythrocytosis

34

8/26

54

40 - 79

Total subjects tested

1096

433/663

58

16 - 88